Biotech · Public company · San Diego, CA, US
Anaptysbio, Inc
Ticker ANAB · SEC CIK 0001370053
Track this companyFree. Adds Anaptysbio, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials82 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- ANB032Phase 2 · Atopic Dermatitis EczemaClinicalTrials.gov · fetched Nov 12, 2026
- EtokimabPhase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- EtokimabPhase 2 · Chronic RhinosinusitisClinicalTrials.gov · fetched Nov 12, 2026
- EtokimabPhase 2 · Eosinophilic AsthmaClinicalTrials.gov · fetched Nov 12, 2026
- EtokimabPhase 2 · Peanut AllergyClinicalTrials.gov · fetched Nov 12, 2026
- Mometasone Furoate Nasal SprayPhase 2 · Chronic RhinosinusitisClinicalTrials.gov · fetched Nov 12, 2026
- RosnilimabPhase 2 · Alopecia AreataClinicalTrials.gov · fetched Nov 12, 2026
- RosnilimabPhase 2 · Rheumatoid ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- RosnilimabPhase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 4, 2023ClinicalTrials.gov NCT06127043 · fetched Nov 12, 2026
- A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 31, 2023ClinicalTrials.gov NCT06041269 · fetched Nov 12, 2026
- This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).PHASE2 · TERMINATED · started Jun 13, 2023ClinicalTrials.gov NCT05935085 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia AreataPHASE2 · UNKNOWN · started Dec 22, 2021ClinicalTrials.gov NCT05205070 · fetched Nov 12, 2026
- Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)PHASE2 · COMPLETED · started Nov 29, 2018ClinicalTrials.gov NCT03614923 · fetched Nov 12, 2026
- Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic DermatitisPHASE2 · COMPLETED · started Jun 19, 2018ClinicalTrials.gov NCT03533751 · fetched Nov 12, 2026
- Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic AsthmaPHASE2 · COMPLETED · started Nov 14, 2017ClinicalTrials.gov NCT03469934 · fetched Nov 12, 2026
- Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut AllergyPHASE2 · COMPLETED · started Jan 26, 2017ClinicalTrials.gov NCT02920021 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 21, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 28, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Apr 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 20, 2026 · fetched Nov 12, 2026